TY - JOUR T1 - Clinical features of hepatic metastasis in patients with ovarian cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 26 LP - 31 DO - 10.1136/ijgc-00009577-200501000-00005 VL - 15 IS - 1 AU - V. Loizzi AU - C. Rossi AU - G. Cormio AU - A. Cazzolla AU - D. Altomare AU - L. Selvaggi Y1 - 2005/01/01 UR - http://ijgc.bmj.com/content/15/1/26.abstract N2 - The purpose of this study was to investigate the clinical features of hepatic metastasis in patients with epithelial ovarian cancer. From 1998 to 2002, all women with hepatic metastasis from ovarian cancer were identified at the University of Bari. Twenty-nine patients identified included one having stage IIC, one stage IIIA, two stage IIIB, 17 stage IIIC, and eight stage IVB. Eight women had hepatic metastasis at the time of the diagnosis of ovarian cancer (group I), 10 patients had hepatic metastasis as first recurrence (group II), and 11 (group III) as a second relapse. The median survival from the time of liver metastasis diagnosis was 19 months in group I patients, 24 months in group II patients, and 10 months in group III patients. No statistical differences in survival were seen among the three groups (P = 0.7). Cell type, performance status at the time of the primary tumor diagnosis, number of hepatic lesions, the presence of other sites of disease at the time of hepatic metastasis, and platinum-based chemotherapy were significantly related to survival. Better performance status, serous cell-type tumor, single hepatic lesion, the absence of other sites of disease, and platinum-based chemotherapy are good prognostic factors. ER -